| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE39069 | ADAMAS OPERATIONS | Multi-layered osmotic device |
May, 2018
(5 years ago) | |
| US8895617 | ADAMAS OPERATIONS | Composition and method for treating neurological disease |
Nov, 2025
(1 year, 6 months from now) | |
| US8895615 | ADAMAS OPERATIONS | Composition and method for treating neurological disease |
Nov, 2025
(1 year, 6 months from now) | |
| US8889740 | ADAMAS OPERATIONS | Composition and method for treating neurological disease |
Nov, 2025
(1 year, 6 months from now) | |
| US8895618 | ADAMAS OPERATIONS | Composition and method for treating neurological disease |
Nov, 2025
(1 year, 6 months from now) | |
| US8895614 | ADAMAS OPERATIONS | Composition and method for treating neurological disease |
Nov, 2025
(1 year, 6 months from now) | |
| US8987333 | ADAMAS OPERATIONS | Composition and method for treating neurological disease |
Nov, 2025
(1 year, 6 months from now) | |
| US9072697 | ADAMAS OPERATIONS | Composition and method for treating neurological disease |
Nov, 2025
(1 year, 6 months from now) | |
| US8796337 | ADAMAS OPERATIONS | Composition and method for treating neurological disease |
Nov, 2025
(1 year, 6 months from now) | |
| US8895616 | ADAMAS OPERATIONS | Composition and method for treating neurological disease |
Nov, 2025
(1 year, 6 months from now) | |
| US8574626 | ADAMAS OPERATIONS | Osmotic device containing amantadine and an osmotic salt |
Nov, 2025
(1 year, 6 months from now) | |
| US8389578 | ADAMAS OPERATIONS | Composition and method for treating neurological disease |
Jan, 2028
(3 years from now) | |
| US8252331 | ADAMAS OPERATIONS | Osmotic device containing amantadine and an osmotic salt |
Mar, 2030
(5 years from now) | |
| US10512617 | ADAMAS OPERATIONS | Composition and method for treating neurological disease |
Feb, 2038
(13 years from now) | |
| US10500170 | ADAMAS OPERATIONS | Composition and method for treating neurological disease |
Feb, 2038
(13 years from now) | |
| US10500171 | ADAMAS OPERATIONS | Composition and method for treating neurological disease |
Feb, 2038
(13 years from now) | |
| US10500172 | ADAMAS OPERATIONS | Composition and method for treating neurological disease |
Feb, 2038
(13 years from now) | |
| US10213394 | ADAMAS OPERATIONS | Composition and method for treating neurological disease |
Feb, 2038
(13 years from now) | |
| US10213393 | ADAMAS OPERATIONS | Composition and method for treating neurological disease |
Feb, 2038
(13 years from now) | |
Osmolex Er is owned by Adamas Operations.
Osmolex Er contains Amantadine Hydrochloride.
Osmolex Er has a total of 19 drug patents out of which 1 drug patent has expired.
Expired drug patents of Osmolex Er are:
- USRE39069
Osmolex Er was authorised for market use on 16 February, 2018.
Osmolex Er is available in tablet, extended release;oral dosage forms.
Osmolex Er can be used as treatment of drug-induced extrapyramidal reactions in adult patients with parkinson's disease, a process for treating a patient suffering from parkinson's syndrome and in need of treatment, treatment of parkinson's disease, treatment of drug-induced extrapyramidal reaction in adult patients.
The generics of Osmolex Er are possible to be released after 15 February, 2038.
Drugs and Companies using AMANTADINE HYDROCHLORIDE ingredient
Market Authorisation Date: 16 February, 2018
Treatment: Treatment of drug-induced extrapyramidal reactions in adult patients with parkinson's disease; Treatment of drug-induced extrapyramidal reaction in adult patients; Treatment of parkinson's disease; A ...
Dosage: TABLET, EXTENDED RELEASE;ORAL
OSMOLEX ER family patents
